ME02560B - Primjena pidotimoda u liječenju psorijaze - Google Patents
Primjena pidotimoda u liječenju psorijazeInfo
- Publication number
- ME02560B ME02560B MEP-2016-277A MEP2016277A ME02560B ME 02560 B ME02560 B ME 02560B ME P2016277 A MEP2016277 A ME P2016277A ME 02560 B ME02560 B ME 02560B
- Authority
- ME
- Montenegro
- Prior art keywords
- pidotimod
- acceptable salt
- pharmaceutically acceptable
- use according
- administered
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title claims 22
- 229960001163 pidotimod Drugs 0.000 title claims 22
- 201000004681 Psoriasis Diseases 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 claims 19
- 238000009472 formulation Methods 0.000 claims 5
- 239000012669 liquid formulation Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims 2
- 229960005339 acitretin Drugs 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 2
- 229960002916 adapalene Drugs 0.000 claims 2
- 229960002459 alefacept Drugs 0.000 claims 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 229960002938 bexarotene Drugs 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 2
- 229960002882 calcipotriol Drugs 0.000 claims 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims 2
- 229960005084 calcitriol Drugs 0.000 claims 2
- 235000020964 calcitriol Nutrition 0.000 claims 2
- 239000011612 calcitriol Substances 0.000 claims 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 229960002199 etretinate Drugs 0.000 claims 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims 2
- 229960002598 fumaric acid Drugs 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 229960005280 isotretinoin Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 2
- 229960005330 pimecrolimus Drugs 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229960004907 tacalcitol Drugs 0.000 claims 2
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960000565 tazarotene Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- 229960003824 ustekinumab Drugs 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940090761 vitamin d and analogues Drugs 0.000 claims 2
- 206010028703 Nail psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (16)
1.Pidotimod ili njegova farmaceutski prihvatljiva so, za primenu u lečenju psorijaze.
2.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 1, karakteristična po tome što navedena psorijaza je psorijaza kože, psorijaza noktiju ili psorijatični artritis.
3.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 1, karakterističan po tome što se daje ljudima.
4.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 1,, karakterističan po tome što se daje sistemski.
5.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 4, karakterističan po tome što se daje u obliku čvrste ili tečne formulacije.
6.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 5, karakterističan po tome navedena čvrsta formulacija je tableta, tableta obložena sa tankim slojem, kapsula, dražeja ili kesica sa prahom.
7.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 5, karakterističan po tome što navedena tečna formulacija je rastvor ili suspenzija.
8.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 5, karakterističan po tome što navedena čvrsta formulacija sadrži tež/tež koncentraciju pidotimoda od 50% do 90%, još bolje od 65% do 80%, najbolje od 70% do 75%.
9.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 5, karakterističan po tome što navedena tečna formulacija ima tež/tež koncentraciju pidotimoda od 0.5% do 20%, još bolje od 1% do 10%, najbolje od 2% do 8%.
10.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 5, karakterističan po tome što formulacija ima sadržaj pidotimoda ili njegove farmaceutski prihvatljive soli, od 10 do 1000 mg po jediničnoj dozi, poželjno je od 50 do 800 mg po jediničnoj dozi.
11.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 1, karakterističan po tome što se daje topično.
12.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 11, karakterističan po tome se daje u obliku polu-čvrste ili tečne formulacije.
13.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 12, karakterističan po tome polu-čvrsta formulacija je krema, gel, mast ili emulzija.
14.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 12, karakterističan po tome što tečna formulacija je rastvor ili suspenzija.
15.Pidotimod ili njegova farmaceutski prihvatljiva so za primenu u skladu sa zahtevom 12, karakterističan po tome što formulacija sadrži tež/tež koncentraciju pidotimoda, ili njegove farmaceutski prihvatljive soli od 0.1% do 20%, još bolje od 1% do 15%, najbolje od 5% do 10%.16.Pidotimod ili njegova fiziološki prihvatljiva so za primenu u skladu sa bilo kojim od prethodnih zahteva, karakterističan po tome što se daje u kombinaciji ili u bliskom vremenskom intervalu sa najmanje još jednim aktivnim principom, gde navedeni bar jedan dodatni aktivni princip je odabran od imunosupresivnih agenasa, poželjno je metotreksata, azatioprina, ciklosporina, fumarne kiseline, takrolimusa ili pimekrolimusa i kortikosteroida, Vitamina D i analoga, poželjno je kalcitriol, kalcipotriol i takalcitol, Vitamin A povezana jedinjenja, poželjno je retinoidi, tretinoin, izotretinoin, etretinat, acitretin, tazaroten, beksaroten i adapalen, biologici, poželjno je alefacept, etanercept, i monoklonalna antitela adalimumab, infliksimab, ustekinumab.
16.Pidotimod ili njegova fiziološki prihvatljiva so za primenu u skladu sa bilo kojim od prethodnih zahteva, karakterističan po tome što se daje u kombinaciji ili u bliskom vremenskom intervalu sa najmanje još jednim aktivnim principom, gde navedeni bar jedan dodatni aktivni princip je odabran od imunosupresivnih agenasa, poželjno je metotreksata, azatioprina, ciklosporina, fumarne kiseline, takrolimusa ili pimekrolimusa i kortikosteroida, Vitamina D i analoga, poželjno je kalcitriol, kalcipotriol i takalcitol, Vitamin A povezana jedinjenja, poželjno je retinoidi, tretinoin, izotretinoin, etretinat, acitretin, tazaroten, beksaroten i adapalen, biologici, poželjno je alefacept, etanercept, i monoklonalna antitela adalimumab, infliksimab, ustekinumab.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076088 WO2014094840A1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
| EP12812221.5A EP2934521B1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02560B true ME02560B (me) | 2017-02-20 |
Family
ID=47520054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-277A ME02560B (me) | 2012-12-19 | 2012-12-19 | Primjena pidotimoda u liječenju psorijaze |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (me) |
| EP (1) | EP2934521B1 (me) |
| JP (1) | JP6051315B2 (me) |
| KR (1) | KR20150095773A (me) |
| CN (1) | CN104869994B (me) |
| AR (1) | AR094027A1 (me) |
| AU (1) | AU2012396942A1 (me) |
| BR (1) | BR112015011391A2 (me) |
| CA (1) | CA2887878A1 (me) |
| CY (1) | CY1118645T1 (me) |
| DK (1) | DK2934521T3 (me) |
| EA (1) | EA201591185A1 (me) |
| ES (1) | ES2617235T3 (me) |
| HK (1) | HK1210937A1 (me) |
| HR (1) | HRP20161666T1 (me) |
| HU (1) | HUE031846T2 (me) |
| IL (1) | IL239429A0 (me) |
| LT (1) | LT2934521T (me) |
| MA (1) | MA38155B1 (me) |
| ME (1) | ME02560B (me) |
| MX (1) | MX2015008104A (me) |
| PH (1) | PH12015501210A1 (me) |
| PL (1) | PL2934521T3 (me) |
| PT (1) | PT2934521T (me) |
| RS (1) | RS55436B1 (me) |
| SG (1) | SG11201503270UA (me) |
| SI (1) | SI2934521T1 (me) |
| SM (2) | SMT201700072T1 (me) |
| TN (1) | TN2015000142A1 (me) |
| WO (1) | WO2014094840A1 (me) |
| ZA (1) | ZA201502573B (me) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (en) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod for use in the treatment of inflammation-associated diseases |
| CN109071653A (zh) * | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase |
-
2012
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 SM SM20170072T patent/SMT201700072T1/it unknown
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Withdrawn
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/en active Active
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 HR HRP20161666TT patent/HRP20161666T1/hr unknown
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 HK HK15111635.1A patent/HK1210937A1/xx unknown
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 CA CA2887878A patent/CA2887878A1/en not_active Abandoned
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/en not_active Ceased
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/me unknown
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birner-Gruenberger et al. | Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology | |
| ES2541488T3 (es) | Espuma farmacéutica penetrante | |
| HRP20201250T1 (hr) | Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze | |
| JP2018526325A5 (me) | ||
| ME02560B (me) | Primjena pidotimoda u liječenju psorijaze | |
| AR061317A1 (es) | Agentes para prevenir o tratar enfermedades inflamatorias | |
| BR112016022159B8 (pt) | Pó e método para melhorar a aplicação tópica de um agente de benefício ácido | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| PH12015502307A1 (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| JP2013538214A5 (me) | ||
| RU2017108432A (ru) | Жидкая ингаляционная композиция, содержащая rpl 554 | |
| NZ611606A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| HRP20161604T1 (hr) | Formulacija protutijela protiv il-17 | |
| RU2014105513A (ru) | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом | |
| JP2013039141A5 (me) | ||
| MX2014007969A (es) | Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8. | |
| ES3053508T2 (en) | Liquid pharmaceutical composition of adalimumab | |
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| ITMI20130354A1 (it) | Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie. | |
| JP2009523750A5 (me) | ||
| JP2015510882A5 (me) | ||
| MX359002B (es) | Metodo y composicion para prevenir la interrupcion y agregacion de celulas madre. | |
| FR2996838B1 (fr) | Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte | |
| Omolo et al. | Formulation of pH responsive multilamellar vesicles for targeted delivery of hydrophilic antibiotics | |
| ME02559B (me) | Primjena pidotimoda u liječenju atopičkog dermatitisa |